ClinicalTrials.gg
RecruitingNCT07529717CRIUS-1Updated Oct 9, 2026

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

A Phase 1/2 interventional study of AZD8359 and AZD8359 in Metastatic Prostate Cancer, sponsored by AstraZeneca. Recruiting at 8 sites in 3 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 9, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Planned enrollment
45th of 60
42 · median 110
Started
2026
with 6 others
Phase 1/2
11 of 91
6 open now
Primary completion
2027-11
later than 14 of 28 live
Registered
86th of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 45th largest by planned enrollment of the 60 interventional ones that give a count, is one of 7 that started in 2026, is one of 11 in phase 1/2, reaches primary completion later than 14 of the 28 other live ones, and was the 86th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels and dosing schedules of AZD8359 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD8359 doses in a larger group of participants (dose expansion).

Read the detailed description

This is a first-in-human, modular, Phase I/II, open label, multicenter study of AZD8359, in adult participants with metastatic prostate cancer. The study will consist of study modules, each evaluating the the safety, tolerability, preliminary efficacy, immune cell activation and anti-tumor activity of AZD8359. The study will also characterize the pharmacokinetics and immunogenicity of AZD8359.

03

Conditions studied

  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • Prostate
  • STEAP2
  • T Cell-engaging Antibody
  • CD8
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of adenocarcinoma of the prostate or neuroendocrine differentiated prostate cancer
  • Surgically or medically castrated with serum testosterone levels ≤ 50 ng/dL (≤ 1.75 nmol/L)
  • PSA value at screening should be ≥ 1ng/mL
  • Evidence of disease progression within 6 months prior to screening
  • Part A Participants should have received at least 2 prior approved systemic therapies for prostate cancer with at least one androgen receptor pathway inhibitor and at least one taxane regimen if amenable
  • Part B Participants should have received an androgen receptor pathway inhibitor for hormone sensitive prostate cancer or metastatic castration resistant prostate cancer (mCRPC). No prior taxane treatment for mCRPC is allowed for Module 1 and 2 Part B patients
  • Adequate organ function
  • Body weight ≥ 35 kg

Exclusion criteria

Exclusion Criteria:

  • Any cardiac abnormalities such as or uncontrolled cardiac arrythmias
  • All prior treatment-related adverse events must have resolved to Grade ≤ 2
  • History of Grade ≥ 3 cytokine release syndrome or Grade ≥ 2 immune effector cell-associated neurotoxicity syndrome with prior therapy
  • Active or prior documented or inflammatory disorders within the past 3 years
  • Prior exposure to any STEAP2 targeted agents or TCEs for prostate cancer
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Module 1 - Part A (Dose Escalation)

    Drug: AZD8359

  • Experimental
    Module 2 - Part A (Dose Escalation)

    Drug: AZD8359

  • Experimental
    Module 1/2 - Part B1 (Dose Expansion)

    Drug: AZD8359

  • Experimental
    Module 1/2 - Part B2 (Dose Expansion)

    Drug: AZD8359

Interventions

  • DrugAZD8359

    AZD8359 Monotherapy Administration route 1

  • DrugAZD8359

    AZD8359 Monotherapy Administration route 2

  • DrugAZD8359

    AZD8359 Monotherapy Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 1 (RDE1)

  • DrugAZD8359

    AZD8359 Monotherapy Administration route 1 (Module 1) or administration route 2 (Module 2) at Recommended Dose for Expansion 2 (RDE2)

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)

    Number of participants with AEs, AESIs, SAEs, including AEs leading to discontinuation of study intervention and clinically significant alterations from baseline in laboratory parameters, vital signs, ECGs and physical examination results

    Time frame: From time of Informed Consent to 90 days post last dose of study intervention (up to 3 years)

  2. Number of participants with dose-limiting toxicity (DLT), as defined in the protocol (Part A only)

    A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness

    Time frame: From first study dose to 21 OR 28 days post first dose based on schedule

  3. PSA response rate (Part B only)

    Number of participants with a PSA50 response

    Time frame: Up to 3 years

Secondary outcomes

  1. PSA Response rate (Part A only)

    Number of participants with a PSA50 response

    Time frame: Up to 3 years

  2. PSA Response rate

    Number of participants with a PSA90 response

    Time frame: Up to 3 years

  3. Time to PSA response

    Time taken to achieve a PSA response

    Time frame: Up to 3 years

  4. Duration of PSA response

    Time PSA response lasts

    Time frame: Up to 3 years

  5. Durable PSA response rate

    Percentage of participants who have a confirmed PSA response with a duration of at least 6 months

    Time frame: Up to 3 years

  6. Time to PSA progression

    Time to achieve PSA progression after a PSA response

    Time frame: Up to 3 years

  7. Objective Response Rate (ORR)

    Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1 for soft tissue disease and PCWG3 for bone disease

    Time frame: Up to 3 years

  8. Duration of Response (DoR)

    Time from the date of first Objective Response (OR) until date disease progression or death in the absence of disease progression according to RECIST v1.1 for soft tissue disease and PCWG3 for bone disease

    Time frame: Up to 3 years

  9. Disease Control Rate (DCR)

    Percentage of participants who have a Best Overall Response (BOR) of confirmed Complete Response (CR), Partial Response (PR) or Stable Disease (SD) according to RECIST v1.1 for soft tissue disease and PCWG3 for bone disease

    Time frame: 16 Weeks

  10. Time To Response (TTR)

    Time from study drug administration date until the date of first Objective Response (OR) according to RECIST v1.1 for soft tissue disease and PCWG3 for bone disease

    Time frame: Up to 3 years

  11. Radiographic Progression Free Survival (rPFS)

    The time from the start of study treatment (Part A) or date of randomization (Part B) until disease progression or death in the absence of disease progression according to RECIST 1.1 for soft tissue disease and PCWG3 for bone disease

    Time frame: Up to 3 years

  12. Durable Response Rate (DRR)

    Percentage of participants who have a confirmed best overall response of Complete Response or Partial Response with a duration at specific milestones (e.g., 3 months, 6 months, 12 months)

    Time frame: Up to 3 years

  13. Target Lesion Percentage change

    Percentage change in Target Lesion size according to RECIST v1.1.

    Time frame: Up to 3 years

  14. Overall Survival (OS) 12 months

    Overall Survival at 12 months

    Time frame: 12 months

  15. Overall Survival (OS)

    Median Overall Survival

    Time frame: Up to 3 years

  16. Symptomatic Skeletal Related Events (SSRE)

    Time to first symptomatic skeletal-related events (SSRE)

    Time frame: Up to 3 years

  17. Serum Concentration of AZD8359

    Serum concentrations of the study drug

    Time frame: From first dose through Day 28 after the last study-drug dose, at predefined intervals

  18. Pharmacokinetics of AZD8359 (Cmax)

    Maximum observed plasma concentration of the study drug (Cmax).

    Time frame: From first dose through Day 28 after the last study-drug dose, at predefined intervals

  19. Pharmacokinetics of AZD8359 (AUC)

    Area under the plasma concentration-time curve (AUC)

    Time frame: From first dose through Day 28 after the last study-drug dose, at predefined intervals

  20. Pharmacokinetics of AZD8359 (Tmax)

    The time it takes for study drug to reach the maximum concentration (Tmax)

    Time frame: From first dose through Day 28 after the last study-drug dose, at predefined intervals

  21. Pharmacokinetics of AZD8359 (Clerance)

    The volume of plasma completely cleared of a study drug per unit of time

    Time frame: From first dose through Day 28 after the last study-drug dose, at predefined intervals

  22. Pharmacokinetics of AZD8359 (t1/2)

    Terminal elimination half life of study drug (t1/2)

    Time frame: From first dose through Day 28 after the last study-drug dose, at predefined intervals

  23. Immunogenicity of AZD8359 (ADA)

    The number and percentage of participants who develop detectable anti-drug antibodies (ADA)

    Time frame: From first dose through Day 28 after the last study-drug dose, at predefined intervals

  24. Tumor STEAP2 expression

    STEAP2 expression in tumor as measured by immunohistochemistry (IHC)

    Time frame: Up to 3 years

07

Study locations

5 of 8 sites recruiting
  • Research Site
    Orlando, Florida 32806, United States
    Active, not recruiting

    Not enrolling at this site.

  • Research Site
    East Brunswick, New Jersey 08816, United States
    Recruiting
  • Research Site
    Hackensack, New Jersey 07601, United States
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Providence, Rhode Island 02903, United States
    Completed

    Not enrolling at this site.

  • Research Site
    Darlinghurst, 2010, Australia
    Recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Seoul, 03722, South Korea
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2027, 17 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 17 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 14, 2026
StartActual
May 18, 2026
Primary completionEst.
Nov 17, 2027
CompletionEst.
Nov 17, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (1 now active, not recruiting, 1 now withdrawn, …)
Show 3 sites
  • Research Site · Orlando, United StatesRecruiting→Active, not recruiting
  • Research Site · Hackensack, United StatesNot yet recruiting→Withdrawn
  • Research Site · Providence, United StatesRecruiting→Completed
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    3 sites changed recruiting status (1 now active, not recruiting, 1 now withdrawn, …)
    Show 3 sites
    • Research Site · Orlando, United StatesRecruiting→Active, not recruiting
    • Research Site · Hackensack, United StatesNot yet recruiting→Withdrawn
    • Research Site · Providence, United StatesRecruiting→Completed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07529717
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
May 18, 2026
Primary completion
Nov 17, 2027 (estimated)
Completion
Nov 17, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion